Nearly 6.7 million adults in the U.S. have heart failure, with prevalence expected to rise to 8.5 million by 20301,2. While heart failure is a chronic, progressive disease, advances in technology are ...

A wireless implantable device that remotely monitors pulmonary artery pressure offers reliable safety and is linked to a significant reduction in the risk for heart failure-related hospitalisation.

Prospective data from the CHAMPION study shows that after 31 months of follow-up, heart failure patients managed with the CardioMEMS HF System had a 48 percent reduction in heart failure ...

St. Jude Medical, Inc., a global medical device company, today announced a new analysis published in the Journal of the American College of Cardiology: Heart Failure shows pulmonary artery (PA) ...

Please provide your email address to receive an email when new articles are posted on . The FDA today announced approval of the CardioMEMS HF System, which measures pulmonary artery pressure and heart ...

St. Jude Medical Inc. ( STJ) has revealed a retrospective data analysis from its CHAMPION trial, conducted to evaluate the safety and efficacy of its CardioMEMS Heart Failure (HF) System on patients ...

New analysis from the CHAMPION trial shows the CardioMEMS™HF System provides a 43% reduction in HF hospitalizations and 53% improvement in survival of CRT/ICD class III HF patients. An economic ...

Please provide your email address to receive an email when new articles are posted on . The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee did not recommend approval of ...

St. Jude Medical is pioneering heart failure disease management with innovative solutions like the CardioMEMS HF System, ground-breaking quadripolar technology, our first-to-market MultiPoint ™ Pacing ...